Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Net
Ratios

Mimedx (MDXG) EBIAT (2016 - 2025)

Mimedx's EBIAT history spans 15 years, with the latest figure at $15.2 million for Q4 2025.

  • For Q4 2025, EBIAT rose 98.76% year-over-year to $15.2 million; the TTM value through Dec 2025 reached $48.6 million, up 14.52%, while the annual FY2025 figure was $48.6 million, 14.52% up from the prior year.
  • EBIAT for Q4 2025 was $15.2 million at Mimedx, down from $16.7 million in the prior quarter.
  • Across five years, EBIAT topped out at $42.1 million in Q4 2023 and bottomed at -$10.9 million in Q2 2022.
  • The 5-year median for EBIAT is $4.1 million (2023), against an average of $4.9 million.
  • The largest annual shift saw EBIAT crashed 510.91% in 2022 before it soared 10263.53% in 2023.
  • A 5-year view of EBIAT shows it stood at $199000.0 in 2021, then crashed by 308.04% to -$414000.0 in 2022, then skyrocketed by 10263.53% to $42.1 million in 2023, then crashed by 81.84% to $7.6 million in 2024, then surged by 98.76% to $15.2 million in 2025.
  • Per Business Quant, the three most recent readings for MDXG's EBIAT are $15.2 million (Q4 2025), $16.7 million (Q3 2025), and $9.6 million (Q2 2025).